Labcorp (LH) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Labcorp Holdings Inc. (LH) insider buying and selling: no purchases, 20 sales
137 Form 4 Table I transactions filed with the SEC by Labcorp Holdings Inc. insiders between 2025-11-04 and 2026-08-18 (15-month history): 0 open-market purchases and 20 sales, plus 117 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $2.4M by Schechter Adam H on 2026-03-03.
Labcorp insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Labcorp insiders filed 20 sales worth $13.7M on the open market, and no purchases.
The biggest seller was Schechter Adam H (President & CEO): $8.4M in 5 sales, out of 10 different sellers.
The largest trade of the period was a sale of $2.4M on Mar 3, 2026, by Schechter Adam H (President & CEO). Form 4 on sec.gov (0000920148-26-000114).
Of the 20 sales, 14 (70%, $8.2M) carry the 10b5-1 plan flag on the Form 4, meaning they were scheduled months ahead; the other 6 do not.
The last three months show 4 sales, against 4 in the three before. The latest sale from Aug 17, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Labcorp has more sales than 46 of the other 58, ranks 33 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with LH's sales, largest first. The full history is in the tool above, already searched.
See all 137 LH trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-03-03 | 2026-03-05 | Schechter Adam H | President & CEO | $2.4M | S — Open-market sale | SEC |
| 2025-10-31 | 2025-11-04 | Parham Richelle P | Director | $1.8M | S — Open-market sale | SEC |
| 2025-11-11 | 2025-11-13 | Schechter Adam H | President & CEO | $1.5M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. | SEC |
| 2026-05-11 | 2026-05-13 | Schechter Adam H | President & CEO | $1.5M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. | SEC |
| 2026-02-11 | 2026-02-13 | Schechter Adam H | President & CEO | $1.5M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. | SEC |
| 2026-08-11 | 2026-08-12 | Schechter Adam H | President & CEO | $1.5M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. | SEC |
| 2026-08-17 | 2026-08-18 | Anderson Kerrii B | Director | $954k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. | SEC |
| 2026-08-03 | 2026-08-05 | Wilkinson Peter J | SVP, Chief Accounting Officer | $439k | S — Open-market sale | SEC |
| 2026-03-27 | 2026-03-30 | Wilkinson Peter J | SVP, Chief Accounting Officer | $436k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF3 Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. | SEC |
| 2026-02-24 | 2026-02-26 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | $429k | S — Open-market sale | SEC |
| 2026-08-04 | 2026-08-06 | Summy Amy B. | EVP, Chief Marketing Officer | $283k | S — Open-market sale | SEC |
| 2026-03-27 | 2026-03-30 | Meltzer Jonathan C | EVP, Operations | $224k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF3 Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. | SEC |
| 2026-06-08 | 2026-06-10 | Kyle Kathryn W | EVP, Chief Legal Officer | $201k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. | SEC |
| 2026-02-19 | 2026-02-23 | Wilkinson Peter J | SVP, Chief Accounting Officer | $185k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. | SEC |
| 2026-02-27 | 2026-03-03 | Van Der Vaart Sandra D | EVP, Corporate Affairs | $156k | S — Open-market sale | SEC |
| 2026-07-02 | 2026-07-06 | Vaughn Bryan T | EVP and President, Diagnostics | $67k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF3 Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. | SEC |
| 2026-07-02 | 2026-07-06 | Kyle Kathryn W | EVP, Chief Legal Officer | $26k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF3 Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. | SEC |
| 2026-02-12 | 2026-02-13 | Meltzer Jonathan C | EVP, Operations | $25k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF3 Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. | SEC |
| 2026-02-10 | 2026-02-12 | Meltzer Jonathan C | EVP, Operations | $25k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. | SEC |
| 2026-02-09 | 2026-02-10 | Meltzer Jonathan C | EVP, Operations | $24k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF3 Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Nov 4, 2025 and Aug 18, 2026 there is not one open-market purchase of Labcorp Holdings Inc.: 20 sales worth $13.7M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Labcorp Holdings Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| F | Tax withholding (shares surrendered for taxes) | 54 | $15.3M |
| M | Option exercise | 51 | $280k |
| S | Open-market sale | 20 | $13.7M |
| A | Grant or award | 12 | $0 |
| Total | Everything filed in the period | 137 | $29.3M |
62 of the 137 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 21 distinct people or entities have filed Labcorp Holdings Inc. transactions: none bought on the open market and 10 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 10 who sold on the open market (20 sales in all), the three biggest sellers account for $11.3M of the $13.7M: 82% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Schechter Adam H | President & CEO | 13 | — | $8.4M (5) | 2026-08-12 |
| Parham Richelle P | Director | 2 | — | $1.8M (1) | 2026-02-13 |
| Wilkinson Peter J | SVP, Chief Accounting Officer | 12 | — | $1.1M (3) | 2026-08-05 |
| Anderson Kerrii B | Director | 2 | — | $954k (1) | 2026-08-18 |
| Caveney Brian J | EVP, Pres of ED, CMO & CSO | 9 | — | $429k (1) | 2026-03-30 |
| Meltzer Jonathan C | EVP, Operations | 12 | — | $299k (4) | 2026-03-30 |
| Summy Amy B. | EVP, Chief Marketing Officer | 9 | — | $283k (1) | 2026-08-06 |
| Kyle Kathryn W | EVP, Chief Legal Officer | 12 | — | $227k (2) | 2026-07-06 |
Shown here are the 8 who moved the most money, out of 21. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Feb 2026: 0 purchases and 7 sales, worth $2.3M. 7 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 1 | $1.8M |
| Nov 2025 | 0 | $0 | 1 | $1.5M |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 7 | $2.3M |
| Mar 2026 | 0 | $0 | 3 | $3.1M |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 1 | $1.5M |
| Jun 2026 | 0 | $0 | 1 | $201k |
| Jul 2026 | 0 | $0 | 2 | $93k |
| Aug 2026 | 0 | $0 | 4 | $3.2M |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Labcorp Holdings Inc. (LH) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
14 of the 20 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Labcorp has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Aug 18, 2026, and a Form 4 arrives up to two business days after the trade.
14 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.